Activation of the PIK3CA/AKT Pathway Suppresses Senescence Induced by an Activated RAS Oncogene to Promote Tumorigenesis

Drexel University College of Medicine, Philadelphia, PA 19129, USA
Molecular cell (Impact Factor: 14.02). 04/2011; 42(1):36-49. DOI: 10.1016/j.molcel.2011.02.020
Source: PubMed

ABSTRACT Mutations in both RAS and the PTEN/PIK3CA/AKT signaling module are found in the same human tumors. PIK3CA and AKT are downstream effectors of RAS, and the selective advantage conferred by mutation of two genes in the same pathway is unclear. Based on a comparative molecular analysis, we show that activated PIK3CA/AKT is a weaker inducer of senescence than is activated RAS. Moreover, concurrent activation of RAS and PIK3CA/AKT impairs RAS-induced senescence. In vivo, bypass of RAS-induced senescence by activated PIK3CA/AKT correlates with accelerated tumorigenesis. Thus, not all oncogenes are equally potent inducers of senescence, and, paradoxically, a weak inducer of senescence (PIK3CA/AKT) can be dominant over a strong inducer of senescence (RAS). For tumor growth, one selective advantage of concurrent mutation of RAS and PTEN/PIK3CA/AKT is suppression of RAS-induced senescence. Evidence is presented that this new understanding can be exploited in rational development and targeted application of prosenescence cancer therapies.

Download full-text


Available from: Indrani Manoharan, May 12, 2014
1 Follower
271 Reads
    • "Expression of Braf V600E in mouse melanocytes results in the formation of benign melanocytic proliferations akin to human nevi (Dankort et al., 2009; Dhomen et al., 2009; Goel et al., 2009). Mouse models have shown that constitutive activation of PI3K/Akt signaling through loss of Pten relieves OIS induced by Ras/Raf mutations in vivo (Dankort et al., 2009; Kennedy et al., 2011; Vredeveld et al., 2012), an observation consistent with analyses of human melanocytic lesions (Vredeveld et al., 2012). These observations suggest that downstream substrates of activated PI3K/Akt signaling are critical in mediating bypass of OIS, though, as such pathway substrates are numerous, the critical factors regulating this effect are unknown. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Braf(V600E) induces benign, growth-arrested melanocytic nevus development, but also drives melanoma formation. Cdkn2a loss in Braf(V600E) melanocytes in mice results in rare progression to melanoma, but only after stable growth arrest as nevi. Immediate progression to melanoma is prevented by upregulation of miR-99/100, which downregulates mTOR and IGF1R signaling. mTORC1 activation through Stk11 (Lkb1) loss abrogates growth arrest of Braf(V600E) melanocytic nevi, but is insufficient for complete progression to melanoma. Cdkn2a loss is associated with mTORC2 and Akt activation in human and murine melanocytic neoplasms. Simultaneous Cdkn2a and Lkb1 inactivation in Braf(V600E) melanocytes results in activation of both mTORC1 and mTORC2/Akt, inducing rapid melanoma formation in mice. In this model, activation of both mTORC1/2 is required for Braf-induced melanomagenesis. Copyright © 2015 Elsevier Inc. All rights reserved.
    Cancer Cell 01/2015; 27(1):41-56. DOI:10.1016/j.ccell.2014.11.014 · 23.52 Impact Factor
  • Source
    • "The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is activated downstream of RAS signaling and likely represents a major mediator of RAS-driven oncogenesis910. In human pancreatic cancer, the PI3K/Akt/mTOR pathway is deregulated in the majority of tumors111213, and the activation of this pathway correlates significantly with a poor prognosis14. Based on these findings, these signaling pathways are potential candidates for targeted therapies. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic cancer is characterized by near-universal mutations in KRAS. The mammalian target of rapamycin (mTOR), which functions downstream of RAS, has divergent effects on stem cells. In the present study, we investigated the significance of the mTOR pathway in maintaining the properties of pancreatic cancer stem cells. The mTOR inhibitor, rapamycin, reduced the viability of CD133(+) pancreatic cancer cells and sphere formation which is an index of self-renewal of stem-like cells, indicating that the mTOR pathway functions to maintain cancer stem-like cells. Further, rapamycin had different effects on CD133(+) cells compared to cyclopamine which is an inhibitor of the Hedgehog pathway. Thus, the mTOR pathway has a distinct role although both pathways maintain pancreatic cancer stem cells. Therefore, mTOR might be a promising target to eliminate pancreatic cancer stem cells.
    Scientific Reports 11/2013; 3:3230. DOI:10.1038/srep03230 · 5.58 Impact Factor
  • Source
    • "Ras family small GTPases play essential roles in a variety of cellular responses including cell proliferation, differentiation, survival, transformation, and tumor development [1] [2] [3] [4]. The family has approximately 20 members in mammals [5] [6], and as many as 36 Ras family genes have been identified in humans [7] with evolutionarily conserved orthologs in Drosophila, C. elegans, S. cerevisiae, S. pombe, Dictyostelium, and plants [8]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The Ras oncogene of silkworm pupae (Bras2) may belong to the Ras superfamily. It shares 77% of its amino acid identity with teratocarcinoma oncogene 21 (TC21) related ras viral oncogene homolog-2 (R-Ras2) and possesses an identical core effector region. The mRNA of Bombyx mori Bras2 has 1412 bp. The open reading frame contains 603 bp, which encodes 200 amino acid residues. This recombinant BmBras2 protein was subsequently used as an antigen to raise a rabbit polyclonal antibody. Western blotting and real-time PCR analyses showed that BmBras2 was expressed during four developmental stages. The BmBras2 expression level was the highest in the pupae and was low in other life cycle stages. BmBras2 was expressed in all eight tested tissues, and it was highly expressed in the head, intestine, and epidermis. Subcellular localization studies indicated that BmBras2 was predominantly localized in the nuclei of Bm5 cells, although cytoplasmic staining was also observed to a lesser extent. A cell proliferation assay showed that rBmBras2 could stimulate the proliferation of hepatoma cells. The higher BmBras2 expression levels in the pupal stage, tissue expression patterns, and a cell proliferation assay indicated that BmBras2 promotes cell division and proliferation, most likely by influencing cell signal transduction.
    International Journal of Genomics 05/2013; 2013:269609. DOI:10.1155/2013/269609 · 0.95 Impact Factor
Show more